Figure 1

Abbreviations: EASI = Eczema Area and Severity Index; IGA = Investigator's Global Assessment; n = number; Q2W = once every 2 weeks; Q4W = once every 4 weeks; SC = subcutaneous; W = week.

[a] Weeks 12 and 20 are phone visits.

[b] 30-day screening window.

[c] Lebrikizumab loading dose of 500 mg SC will be administered at baseline and Week 2.

[d] Responders: Participants who reach IGA 0 or 1 (clear or almost clear) or a 75% reduction in the EASI score from baseline (EASI-75). Inadequate responders are participants who do not reach these criteria.

[e] The safety follow-up visit will occur approximately 12 weeks after last study intervention injection.

Figure 2

Post-inflammatory hypopigmentation
Post-inflammatory hyperpigmentation
-3
-2
-1
0
+1
+2
+3
Severe hypopigmentation
Moderate hypopigmentation
Mild hypopigmentation
Normal skin tone
Mild hyperpigmentation
Moderate hyperpigmentation
Severe hyperpigmentation
Prominent hypopigmentation
Clearly perceptible hypopigmentation
Barely perceptible hypopigmentation
Barely perceptible hyperpigmentation
Clearly perceptible hyperpigmentation
Prominent hyperpigmentation

Figure 3A

	LEBRI 250mg Q2W (N=50)
Age, years, mean (SD)	42.2 (19.7)
Adult (≥18 years)	42 (84.0)
Adolescent (≥12 to <18 years)	8 (16.0)
Female	23 (46.0)
Race	
Black or African American	40 (80.0)
Asian	7 (14.0)
American Indian or Alaska Native	3 (6.0)
Other	0 (0.0)
Ethnicity	
Hispanic or Latino	11 (22.0)
Not Hispanic or Latino	39 (78.0)
Fitzpatrick Phototype	
IV	21 (42.0)
V	11 (22.0)
VI	18 (36.0)

Figure 3B

	LEBRI 250mg Q2W (N=50)
Age at AD onset, years	22.8 (22.8)
IGA , n (%)	
3, moderate	32 (64.0)
4, severe	17 (34.0)
EASI	28.1 (12.4)
Pruritus NRS	7.2 (2.2)
≥3, n (%)	40 (93.0)
≥4, n (%)	39 (90.7)
PDCA-Derm™, Patients with ≥1 lesion, n(%)	
Hypopigmented Areas	9 (18.0)
Hyperpigmented Areas	27 (54.0)
% BSA affected	41.7 (20.8)
Sleep Loss scale	2.1 (1.1)
DLQI	13.9 (8.3)
cDLQI	13.0 (9.6)




Figure 4



LEBRI 250 mg Q2W
Patients (%)
Week
100
80
60
40
20
0
0
2
4
8
16
7%
22%
48%
68%

Figure 5

Figure 6



Mean Change from Baseline (%)
0
-20
-40
-60
-80
-100
Week
0
2
4
6
8
10
12
14
16
LEBRI 250 mg Q2W
-16%
-32%
-41%
-44%
-50%
-53%
-55%
-54%

Figure 7A

PDCA-Derm™

	LEB 250 Q2W N=50
Hypopigmented Areas	
Patients with ≥1 lesion, n(%)[b]	9 (18.0)
-1, n(%)[c]	0 (0.0)
-2, n(%)[c]	8 (88.9)
-3, n(%)[c]	1 (11.1)
Hyperpigmented Areas	
Patients with ≥1 lesion, n(%)[b]	27 (54.0)
+1, n(%)[c]	3 (11.1)
+2, n(%)[c]	21 (77.8)
+3, n(%)[c]	3 (11.1)

Footnotes:

[b] Patients with multiple hypopigmented or hyperpigmented lesions at baseline are counted under the most extreme score.

[c] The number of patients with this lesion type is used as the denominator.

Figure 7B

Hyperpigmented Lesions (N=21) [a,b]

Baseline Score	-3 n (%)	-2 n (%)	-1 n (%)	0 n (%)	+1 n (%)	+2 n (%)	+3 n (%)	Total n (%)
+3	0 (0)	0 (0)	0 (0)	1 (4.8)[c,d]	0 (0)	1 (4.8)[c]	0 (0)	2 (9.5)
+2	0 (0)	1 (4.8)[e]	2 (9.5)[e]	3 (14.3)[c,d]	5 (23.8)[c]	5 (23.8)[e]	0 (0)	16 (76.2)
+1	0 (0)	0 (0)	0 (0)	2 (9.5)[c,d]	0 (0)	1 (4.8)[e]	0 (0)	3 (14.3)

Figure 7C

Hypopigmented Lesions (N=5) [a,b]

Baseline Score	-3 n (%)	-2 n (%)	-1 n (%)	0 n (%)	+1 n (%)	+2 n (%)	+3 n (%)	Total n (%)
-3	0 (0)	1 (20)[c]	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (20)
-2	0 (0)	2 (40)[e]	0 (0)	0 (0)	1 (20)[e]	1 (20)[e]	0 (0)	4 (80)
-1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)